394 related articles for article (PubMed ID: 24982311)
1. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
Stobaugh DJ; Deepak P
Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
[TBL] [Abstract][Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
3. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
4. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
5. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
6. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.
Deepak P; Stobaugh DJ
Aliment Pharmacol Ther; 2014 Nov; 40(9):1035-43. PubMed ID: 25164260
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
8. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous side effects caused by treatment for inflammatory bowel disease.
Tarabar D; Kandolf-Sekulović L; Tatomirović Ž; Mijušković Ž; Milenković Z; Tarabar O; Pecelj-Broćić T
Vojnosanit Pregl; 2016 Apr; 73(4):382-9. PubMed ID: 29309107
[No Abstract] [Full Text] [Related]
10. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.
Daperno M; Sostegni R; Canaparo R; Serpe L; Lavagna A; Crocellà L; Castagno F; Vernetto A; Rigazio C; Ercole E; D'Antico S; Pera A; Zara G; Rocca R
Aliment Pharmacol Ther; 2009 Oct; 30(8):843-53. PubMed ID: 19650826
[TBL] [Abstract][Full Text] [Related]
11. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions.
Soh JS; Yun WJ; Kim KJ; Won CH; Park SH; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Kim JH
Inflamm Bowel Dis; 2015 Apr; 21(4):832-9. PubMed ID: 25789922
[TBL] [Abstract][Full Text] [Related]
12. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
13. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
14. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
15. [Two cases of thiopurine-induced acute pancreatitis in inflammatory bowel disease].
Nishikawa J; Kudo T; Miyazaki T; Mihara H; Ueda A; Ando T; Kajiura S; Fujinami H; Ogawa K; Hosokawa A; Sugiyama T
Nihon Shokakibyo Gakkai Zasshi; 2012 Feb; 109(2):224-30. PubMed ID: 22306545
[TBL] [Abstract][Full Text] [Related]
16. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis.
Bermejo F; Lopez-Sanroman A; Taxonera C; Gisbert JP; Pérez-Calle JL; Vera I; Menchén L; Martín-Arranz MD; Opio V; Carneros JA; Van-Domselaar M; Mendoza JL; Luna M; López P; Calvo M; Algaba A
Aliment Pharmacol Ther; 2008 Sep; 28(5):623-8. PubMed ID: 18513380
[TBL] [Abstract][Full Text] [Related]
17. Effect of IBD medications on COVID-19 outcomes: results from an international registry.
Ungaro RC; Brenner EJ; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
Gut; 2021 Apr; 70(4):725-732. PubMed ID: 33082265
[TBL] [Abstract][Full Text] [Related]
18. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
[TBL] [Abstract][Full Text] [Related]
19. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients.
Caldera F; Saha S; Wald A; Garmoe CA; McCrone S; Megna B; Ley D; Reichelderfer M; Hayney MS
Dig Dis Sci; 2018 Jun; 63(6):1532-1540. PubMed ID: 29594970
[TBL] [Abstract][Full Text] [Related]
20. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
Amin J; Huang B; Yoon J; Shih DQ
Inflamm Bowel Dis; 2015 Feb; 21(2):445-52. PubMed ID: 25248004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]